局限期小细胞肺癌治疗新格局:从传统放化疗到精准治疗的新进展OA

Limited-stage small cell lung cancer(LS-SCLC)is a highly aggressive malignancy with a poor progno-sis.For a long time,the standard first-line treatment has been Etoposide plus Platinum-based chemotherapy combined with concurrent thoracic radiotherapy;however,most patients still face recurrence and drug resistance.This article systematically reviews major recent advances in the field,aiming to illustrate the new paradigm shifting from conventional chemoradiotherapy toward precision-integrated therapy.Radiotherapy techniques continue to be optimized,and the value of surgery has been reaf-firmed in rigorously selected early-stage patients;immunotherapy has achieved a milestone breakthrough,with the ADRIATIC trial demonstrating that consolidation therapy with Durvalumab after chemoradiotherapy significantly extends median overall survival(55.9 vs 33.4 months);meanwhile,targeted therapies based on molecular subtyping also show promise.This paper clarifies the optimized directions of multimodal treatment strategies,emphasizes the guiding significance of molecular subtyp-ing and biomarkers in individualized therapy,with the aim of providing reference for clinical practice,offering a framework for future research,and ultimately improving the survival outcomes of LS-SCLC patients as a whole.